
Opinion|Videos|December 8, 2023
Expert Insights in Overcoming Endocrine Resistance for Patients With ER+/HER2- Metastatic Breast Cancer
Author(s)Hope S. Rugo, MD
Expert insights on improving outcomes in ER+/HER2- metastatic breast cancer patients with resistance mutations.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5










































